CG Oncology to Highlight the P-II (CORE-001) Trial Data of Cretostimogene Grenadenorepvec Plus Keytruda for Bladder Cancer at ASCO 2024
Shots:
- The P-II (CORE-001) study assesses the safety & efficacy of cretostimogene + Keytruda to treat high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients (n=35) having carcinoma in situ (CIS) after disease resection
- The results showed CR rates of 57% (20/35; 12mos.) & 83% (29/35; any time) as of Feb 2024 and 54% (19/35; 24mos.) as of May 2024 in ITT population with 77.3% (12mos.) & 69.6% (24mos.) as per Kaplan-Meier estimation; 95% of patients (19/20) in CR sustained it for 12mos. more. 100% PFS with 80% & 100% (patients in CR) CFS at 24mos. was seen; mDoR was not attained but exceeds 21mos.
- Furthermore, the company featured P-III (BOND-003) study data at AUA 2024 depicting sustained durable responses at 12mos. & CRR of 75.2%. Topline data is anticipated by 2024 end with a regulatory approval submission on track
Ref: CG Oncology | Image: CG Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
